Minimizing quinolone resistance: Are the new agents more or less likely to cause resistance?

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 6, 2000, Pages 719-723

  Thomson, Kenneth S ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DRUG POTENCY; EDITORIAL; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

EID: 0034084389     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.6.719     Document Type: Editorial

References (23)

1. Cheek, W. A. (1993). Physicians must rethink use of antibiotics to curb rise in drug-resistant microbes. ACP Observer 13, 15-9.
2. Cherubin, C. E., Smith, S. M., Eng, R. H. K. & Pudi, K. (1992). An extension of quinolone resistance in Gram-negatives of the Proteae tribe and a theory of antibiotic use, 'Pascal's Wager'. Infectious Disease Newsletter 11, 57-9.
3. Köhler, T. & Pechère, J. C. (1998). Bacterial resistance to quinolones. In The Quinolones, 2nd edn, (Andriole, V. T., Ed.), pp. 117-42. Academic Press, San Diego, CA.
4. Peterson, L. R. (1993). Quinolone resistance in clinical practice: occurrence and importance. In Quinolone Antimicrobial Agents, 2nd edn, (Hooper, D. C. & Wolfson, J. S., Eds), pp. 119-37. American Society for Microbiology, Washington, DC.
5. Frieden, T. R. & Mangi, R. J. (1990). Inappropriate use of oral ciprofloxacin. Journal of the American Medical Association 264, 1438-40.
6. Thomson, K. S., Sanders, W. E. & Sanders, C. C. (1994). USA resistance patterns among UTI pathogens. Journal of Antimicrobial Chemotherapy 33, Suppl. A, 9-15.
7. Hooper, D. C. & Wolfson, J. S. (1993). Mechanisms of bacterial resistance to quinolones. In Quinolone Antimicrobial Agents, 2nd edn, (Hooper, D. C. & Wolfson, J. S., Eds), pp. 97-118. American Society for Microbiology, Washington, DC.
8. Oram, M. & Fisher, L. M. (1991). 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 387-9.
9. Sanders, C. C. (1990). Microbiology of fluoroquinolones. In Fluoroquinolones in the Treatment of Infectious Diseases, (Sanders, W. E. & Sanders, C. C., Eds), pp. 1-27. Physicians and Scientists Publishing Co., Glenview, IL.
10. Michéa-Hamzehpour, M., Auckenthaler, R., Regamey, P. & Pechère, J. C. (1987). Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrobial Agents and Chemotherapy 31, 1803-8.
11. Fung-Tomc, J., Kolek, B. & Bonner, D. P. (1993). Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 37, 1289-96.
12. Thomson, K. S. & Sanders, C. C. (1994). Dissociated resistance among fluoroquinolones. Antimicrobial Agents and Chemotherapy 38, 2095-100.
13. Fournier, B. & Hooper, D. C. (1998). Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrobial Agents and Chemotherapy 42, 121-8.
14. Piddock, L. J. V., Johnson, M., Ricci, V. & Hill, S. L. (1998). Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrobial Agents and Chemotherapy 42, 2956-60.
15. Pan, X.-S. & Fisher, L. M. (1998). DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 42, 2810-6.
16. Fournier, B. & Hooper, D. C. (1998). Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrobial Agents and Chemotherapy 42, 2109-12.
17. Thomson, K. S. & Sanders, C. C. (1998). The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Journal of Antimicrobial Chemotherapy 42, 179-87.
18. Thomson, K. S., Moland, E. S. & Sanders, C. C. (1997). Mutational increases in fluoroquinolone resistance. In Economic and Clinical Implications of Ouinolones in Hospital Pharmacy: a poster symposium presented during the Thirty-Second Annual ASHP Midyear Clinical Meeting, Atlanta, GA, 1997. Abstract, pp. 46-7. DesignWrite, Inc., Princeton, NJ.
19. National Committee for Clinical Laboratory Standards. (1999). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Approved Standard M7-A4. NCCLS, Villanova, PA.
20. Pong, A., Thomson, K. S., Moland, E. S., Chartrand, S. A. & Sanders, C. C. (1999). Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. Journal of Antimicrobial Chemotherapy 44, 621-7.
21. Thomson, K. S., Moland, E. S. & Sanders, C. C. (1999). Activity of trovafloxacin against antibiotic-resistant bacterial pathogens. Infectious Diseases in Clinical Practice 8, Suppl. 1, S7-S16.
22. Thomson, K. S., Sanders, C. C. & Hayden, M. E. (1991). In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrobial Agents and Chemotherapy 35, 2329-34.
23. Thomson, K. S., Moland, E. S. & Sanders, C. C. (1999). Activity of gatifloxacin against clinical isolates with various levels of resistance to ciprofloxacin. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 354, p. 248. American Society for Microbiology, Washington, DC.